Document is current
Any future updates will be listed below
-
Authors
Nechanitzky, Duygu
Smith, Logan K.
Nechanitzky, Robert
Jafari, Soode Moghadas
Haight, Jillian
Bontoux, Christophe https://orcid.org/0000-0001-5446-6197
Ramachandran, Parameswaran
Gold, Matthew J.
Wakeham, Andrew C.
Saunders, Mary E.
Deniset, Justin F.
Mak, Tak W. https://orcid.org/0000-0001-6766-861X
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (Application #470754)
Innovation and Technology Commission
Centre for Oncology and Immunology under the Health@InnoHK Initiative funded by the Innovation and Technology Commission, The Government of Hong Kong SAR, China.
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 21 January 2026
First Online: 24 February 2026
Competing interests
: R.N. is employed by Zymeworks BC. M.G. is employed by Providence Therapeutics Holdings. T.W.M. owns equity in Treadwell Therapeutics and Agios Pharmaceuticals, and is a consultant for AstraZeneca and Tessa Therapeutics. The other authors declare no competing interests.
